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Direct bone marrow HSC 
transplantation enhances local 
engraftment at the expense of 
systemic engraftment in NSG mice
Kathryn Futrega1, William B. Lott1 & Michael R. Doran1,2
Direct bone marrow (BM) injection has been proposed as a strategy to bypass homing inefficiencies 
associated with intravenous (IV) hematopoietic stem cell (HSC) transplantation. Despite physical 
delivery into the BM cavity, many donor cells are rapidly redistributed by vascular perfusion, perhaps 
compromising efficacy. Anchoring donor cells to 3-dimensional (3D) multicellular spheroids, formed 
from mesenchymal stem/stromal cells (MSC) might improve direct BM transplantation. To test this 
hypothesis, relevant combinations of human umbilical cord blood-derived CD34+ cells and BM-derived 
MSC were transplanted into NOD/SCID gamma (NSG) mice using either IV or intrafemoral (IF) routes. 
IF transplantation resulted in higher human CD45+ and CD34+ cell engraftment within injected femurs 
relative to distal femurs regardless of cell combination, but did not improve overall CD45+ engraftment 
at 8 weeks. Analysis within individual mice revealed that despite engraftment reaching near saturation 
within the injected femur, engraftment at distal hematopoietic sites including peripheral blood, spleen 
and non-injected femur, could be poor. Our data suggest that the retention of human HSC within the 
BM following direct BM injection enhances local chimerism at the expense of systemic chimerism in this 
xenogeneic model.
Umbilical cord blood (CB)-derived hematopoietic stem cells (HSC) are ideal for use in allogeneic HSC transplan-
tation when a compatible adult donor is unavailable. However, the limited number of HSC per unit of CB delays 
engraftment and may be associated with graft failure and/or mortality1. The limited cell number is compounded 
by the inefficiency with which the transplanted cells home to the patient’s bone marrow (BM). To overcome cell 
number and homing limitations, a number of strategies have been trialed including transplantation of multiple 
CB units, ex vivo expansion prior to transplantation, manipulation of the cell graft to enhance homing efficiency, 
and direct BM injection.
Two recent clinical trials, one using immobilized Notch ligand2 and the other using mesenchymal stem/
stromal cell (MSC) co-culture3, demonstrated that ex vivo expansion could increase the CD34+ progenitor cell 
number by 100- or 40-fold, respectively. In both cases the expanded progenitor cells facilitated rapid myeloid 
reconstitution, but did not contribute to long-term hematopoiesis in the human recipients. Despite significant 
advancements in the field, strategies that maintain populations of long-term repopulating HSC during extended 
ex vivo expansion remain elusive4. Until this barrier is overcome, ex vivo expanded CB units must be supple-
mented with a unit of unmanipulated CB, significantly increasing the total cost of the therapy4. This significant 
cost has motivated investment into potentially more cost-effective strategies such as those that may improve the 
efficiency by which donor cells home to the recipient’s marrow.
In mouse models5 and a phase I clinical trial6, a brief 2 hour pre-treatment of CB cells with 16,16-Dimethyl 
prostaglandin E2 (PGE2) significantly enhanced cell homing efficiency. While the total number of CD34+ cells 
that homed to the murine BM was not reported, the frequency of CD34+ cells in the murine femurs increased by 
~50% when the transplanted cells were pre-treated with PGE2. Data from the associated human trial indicated 
a promising trend in neutrophil and platelet recovery kinetics, and critically, the manipulated cells continued to 
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contribute to hematopoiesis up to the time of publication (27 months)6. Similarly, a recent study from Shpall’s 
group demonstrated that enzymatically fucosylated CB cells had enhanced homing capacity leading to improved 
clinical outcomes7.
Theoretically, direct BM injection should enable bypassing aspects of the homing process and reduce donor 
cell loss to non-hematopoietic organs. There is evidence in murine models that direct BM transplantation is 
superior to intravenous transplantation when donor cell numbers are limiting8,9 or when transplanting cells with 
impaired homing capacity10. However, this has not translated to improvements in human CB transplant outcomes 
in the clinic11. While recent failure to demonstrate benefit in the clinic will likely deter near-term human studies, 
the conceptual merits of direct BM transplantation coupled with controversial animal model results8,12–17 could 
continue to drive research in this area. The most agreed upon limitation in current direct BM injection methods 
is that donor cells are not necessarily retained within the injected marrow. Legitimizing this concern are studies 
suggesting that only ~10% of donor cells are physically retained in the injected marrow even 5 minutes post trans-
plantation17. Not only does vascular perfusion redistribute injected cells, the proximal delivery of these cells into 
the BM cavity may itself be insufficient to functionally replace active homing or retention. In studies where the 
CXCR4 receptor was blocked on donor cells, delivery into the BM did not rescue engraftment capacity18. These 
results suggest that active homing processes are necessary for engraftment, regardless of delivery route. Resolving 
the debate as to whether failure to retain donor cells within the injected marrow is the limiting factor would 
require experimentation involving the anchorage of the donor cells within the marrow using a material, which 
itself does not compromise donor cell function.
Assuming donor cell retention in the injected marrow was a limiting factor, we hypothesized that engraftment 
following direct BM transplantation could be improved if donor HSC were anchored to multicellular BM-derived 
mesenchymal stromal cell (MSC) spheroids. Studies suggest that the biological potency of MSC, and specifically 
their HSC-supportive capacity, is increased when these cells are assembled into 3-dimensional (3D) spheroids19,20, 
making MSC spheroids an appropriate biologically active anchor. Herein, we describe a high-throughput microw-
ell platform to manufacture thousands of multicellular spheroids, each formed from approximately 110 MSC and 
10 CB-derived CD34+ cells. Spheroids formed spontaneously when the CD34+ cells and MSC were co-cultured 
for 24 hours, and the spheroid diameter (< 100 μm) was tailored to enable direct BM injection using a fine 
27-gauge needle. We used a short culture period (24 hours) to minimize the negative impact of ex vivo expansion 
on long-term HSC engraftment. To test our hypothesis, we compared four transplant conditions in sub-lethally 
irradiated NOD/SCID gamma (NSG) mice: (1) intravenous (IV) injection of CD34+ cells, (2) intrafemoral (IF) 
injection of CD34+ cells, (3) IF injection of CD34+ cells and MSC in suspension, and (4) IF injection of CD34+ 
cells and MSC organized into 3D spheroids (summarized in Fig. 1).
Results
MSC isolation, culture and characterization. Adult BM-derived MSC met the typical criteria defined 
for MSC (see Supplementary Figure 1) including plastic-adherent, differentiated to adipocytes, osteoblasts and 
Figure 1. Schematic of experimental groups to test engraftment delivery strategies. Cultures were prepared 
as described schematically and injected in irradiated NSG mice via IV or IF transplants, 24-hours later.
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chondrocytes, and expressed surface antigens CD44, CD73, CD90, CD105, CD146, and lacked the expression of 
hematopoietic markers, CD45, CD34 and HLA-DR.
Characterization of CD34+ and MSC 2D and 3D co-cultures. We characterized both 2D and 3D 
co-cultures at 24 hours. Figure 2A–D show the 2D co-cultures and Fig. 2E–L show the development of 3D 
co-cultures. CD34+ cells were labeled with CFSE (green) and MSC labeled with CMPTX (red). Figure 2E–I shows 
the assembly of 3D spheroids consisting of labeled CD34+ cells and MSC at time zero in microwells. Figure 2J–L 
show the 3D spheroids after they had been depleted of loose CD34+ cells. Through manual counting we found 
that on average, 3 CD34+ cells were attached to a MSC spheroid, following 24-hours.
NSG engraftment. Engraftment in the BM, peripheral blood and spleen were characterized via flow cytom-
etry. Supplementary Figure 2 provides an example of the gating strategy used for flow cytometry analysis. Figure 3 
displays individual mouse and median hCD45 engraftment observed at 8 weeks post transplant in (A) the periph-
eral blood, (B) spleen, (C) right & left femurs, and (D) the average of both femurs. When CD34+ cells only (no 
MSC) were delivered via IV or IF injection, the median peripheral blood engraftment was similar in these groups 
(Fig. 3A). When CD34+ cell IF transplants were co-transplanted with a suspension of MSC, there was an incre-
mental reduction (not statistically significant) in peripheral blood engraftment relative to IV or IF transplanta-
tion containing CD34+ cells only. hCD45 engraftment was significantly lower in the spleen when MSC where 
co-transplanted with CD34+ cells through IF injection (Fig. 3B), relative to IV CD34+ transplants. A statistically 
significant decrease in peripheral blood and spleen engraftment was observed in animals that received IF CD34+ 
cell transplants with 3D MSC spheroids, relative to IF CD34+ cells alone. Overall, peripheral blood and spleen 
engraftment was similar between IF and IV transplant groups receiving CD34+ cells alone, while engraftment 
appeared to be incrementally compromised in IF groups with the addition of MSC in suspension or in spheroids.
We subsequently contrasted hCD45 engraftment between femurs in all animals. Engraftment in left and right 
femurs did not differ significantly in individual mice following IV human cell transplantation (Fig. 3C). Given the 
relatively uniform total body irradiation used in the conditioning procedure, uniform BM engraftment following 
IV transplantation was not surprising. In contrast to IV results, but similar to previous reports8,12,17, IF trans-
plantation resulted in greater hCD45 engraftment within injected right femurs (RF) relative to distal left femurs 
(LF). The relative human engraftment between femurs in individual mice is shown graphically in Supplementary 
Figure 2. Images of 2D and 3D co-cultures. (A–D) 2D CD34+/MSC co-culture after 24 hours. (B) Phase 
contrast, (C) CD34+ cells labeled with CFSE (green), and (D) MSC labeled with CMPTX (red). Scale bars 
B–D = 400 μm. (E–I) 3D CD34+/MSC co-culture before (F–I) and after 24 hours (J–L). (F) Phase contrast 
image of microwells at time zero, (G) MSC labeled with CMPTX (red) time zero, (H) CD34+ cells labeled with 
CFSE (green) time zero, (I) overlay of labeled CD34+ and MSC at time zero; (J) Phase contrast of spheroids 
(4× ) after 24 hour culture, (K) fluorescent image (4× ), (L) 3D CD34+/MSC spheroids (confocal image, 20× ). 
Scale bars (F–I) = 400 μm, Scale bar (J,K) = 1 mm, Scale bar (L) = 100 μm.
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Figure 3A–D. While hCD45 engraftment was always greater within injected femurs (RF), the BM hCD45 content 
was not different between experimental groups (groups 1–4) when the injected and distal femur BM hCD45 
numbers were averaged (Fig. 3D).
We further evaluated the lineage composition of the hCD45 populations between femurs, peripheral blood 
and spleen of mice. The relative CD34+ progenitor cell content was similar in both femurs following IV trans-
plantation (Fig. 3E). By contrast, the CD34+ cell content, was significantly greater in injected femurs than in 
non-injected femurs following IF transplantation. In a previous study, a similar pattern was interpreted as either 
the increased retention of progenitor cells within the injected femur or an increased rate of local self-renewal 
Figure 3. Human engraftment in peripheral blood (PB), spleen (SP), and bone marrow (BM) at 8 weeks. 
Cells in IV transplant were injected retro-orbitally, and in IF transplants, cells were injected into the right femur 
(RF; asterisk next to RF denotes “injected” femur). (A) hCD45 peripheral blood (PB) engraftment at 8 weeks. 
(B) hCD45 engraftment in spleens (SP). (C) hCD45 engraftment in both BM or each individual femur (LF and 
*RF). (D) Average LF and RF BM hCD45 engraftment. (E) hCD34 cell numbers in each femur (LF and *RF).  
(F) Average LF and RF BM hCD34 engraftment. (*P < 0.05, **P < 0.01, and ***P < 0.001).
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within injected femurs17. To determine if other lineage populations were different between femurs of individual 
animals, we quantified the relative CD19+ (B cell), CD33+ (myeloid), and CD15+ (granulocyte) lineage com-
mitted cells in each femur, peripheral blood and spleen (Supplementary Figures 4 and 5). The portion of hCD45 
cells that were CD19+, CD33+, or CD15+ was similar in the femurs of mice from all four transplant groups 
(Supplementary Figure 5). CD15+ human cells were rare (≤ 1% - data not shown) in the peripheral blood and 
spleen. Relative numbers of human CD33+ and CD19+ cells found in the peripheral blood and spleen are shown 
in Supplementary Figure 5. Overall, with the exception of CD34+ cell content in the injected and distal femurs of 
IF animals, human hematopoietic lineage populations were similar across all groups.
The significantly different hCD45+ and CD34+ progenitor cell content between injected and distal femurs 
indicated that BM engraftment within individual mice was heterogeneous and dependent on delivery site. To 
probe this further, the hCD45 engraftment ratio between the injected femur (RF) and distal femur (LF) was calcu-
lated (referred to as “RF/LF ratio”). The RF/LF ratio is a measure of the engraftment heterogeneity within a single 
animal. An RF/LF ratio of 1 represents an equal distribution of hCD45 cells engrafted between femurs, and sug-
gests that engraftment within that individual animal was relatively homogenous. An RF/LF ratio of 10, for exam-
ple, indicates that the engraftment in the injected femur (RF) was 10-fold greater than in the non-injected femur 
(LF) and that the engraftment was heterogeneous. The RF/LF ratios were plotted against hCD45 engraftment in 
peripheral blood, spleen, non-injected distal femur (LF), and injected femur (*RF) for each animal (Fig. 4A–D, 
respectively).
Animals with the highest levels of peripheral blood engraftment (top 15 out of 60 animals) had RF/LF ratios 
≤ 2 (Fig. 4A), suggesting that high levels of engraftment were consistent with more equal distribution of donor 
cells between femurs. By contrast, lower levels of peripheral blood engraftment were associated with RF/LF ratios 
> 2, suggesting that failure to achieve homogenous BM engraftment was associated with lower overall periph-
eral blood chimerism. IV transplants generally resulted in RF/LF ratios closer to 1, indicating that this method 
provided relatively uniform BM engraftment. This analysis is consistent with the graphical data in Fig. 3E and 
Supplementary Figure 2A, which shows that engraftment within injected and non-injected femurs was similar in 
IV transplanted mice.
Engraftment was always greater in injected femurs, and larger RF/LF ratios were more common in IF 
transplanted mice. The engraftment pattern in the spleens and non-injected femurs, relative to RF/LF ratios 
(Fig. 4B,C), was similar to the relative pattern observed for peripheral blood engraftment (Fig. 4A). This suggested 
that peripheral blood engraftment paralleled the engraftment patterns in the distal hematopoietic organs (LF and 
spleen). By contrast, no pattern was observed when the RF/LF ratio was plotted relative to hCD45 engraftment in 
the injected femur (Fig. 4D). This suggested that there was disconnect between engraftment in the injected femurs 
and engraftment in the distal organs.
Figure 4. Relationship between hCD45 engraftment in specified tissues relative to the RF/LF ratio. RF/
LF ratio is the hCD45 engraftment in the injected femur (RF) divided by the hCD45 engraftment in the non-
injected femur (LF). (A) Graphical relationship between peripheral blood hCD45 engraftment and the RF/
LF ratio. (B) Graphical relationship between spleen hCD45 engraftment and the RF/LF ratio. (C) Graphical 
relationship between the distal non-injected femur (LF) hCD45 engraftment and the RF/LF ratio. (D) Graphical 
relationship between hCD45 engraftment in the injected femur (*RF) and the RF/LF ratio.
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The most striking data are enclosed within the “boxed” region of Fig. 4D, which identifies ~25% of mice 
with the highest levels of hCD45 engraftment within the injected femurs. All mice within this boxed region had 
RF/LF ratios > 2. This implies that engraftment in the distal marrow of these animals was less than half of that 
observed within the injected marrow. In the most extreme case, the distal femur in one animal contained 10-fold 
fewer hCD45 cells than the injected femur. This observation is profound, as the injected femur in this animal 
was virtually saturated with hCD45 cells (> 90% hCD45). These data suggest that saturation of the injected BM 
with human cells did not necessarily translate to high levels of systemic engraftment in the distal BM, spleen 
or peripheral blood. This engraftment phenomenon was only observed in animals that received IF transplants 
(Fig. 4D, red, green and blue data points), and was not observed in animals that received IV transplants (Fig. 4D, 
open circle data points).
Discussion
Previous reports suggest that the efficacy of IF transplantation may be limited by the failure of injected cells to 
be retained within the injected marrow17. MSC spheroids are viable biological anchors that could be potentially 
used to retain donor HSC within the injected marrow. Assembling MSC into spheroids has been previously 
shown to enhance their secretion of HSC-supportive factors19,20. The enhanced supportive environment, coupled 
with anchorage, make MSC an ideal tool for CD34+ cell retention following IF transplant. Intriguingly, we found 
that anchoring CD34+ cells to MSC spheroids during IF transplantation compromised overall peripheral blood 
engraftment, relative to IF transplantation of CD34+ cells alone. This observation led us to carefully consider the 
hypothesis that anchorage could improve IF transplant outcomes, and asked the question: does retention of donor 
CD34+ cells within the injected femurs actively compromise engraftment outcomes?
While direct BM transplantation did not improve overall peripheral blood engraftment, greater local hCD45 
and CD34 content was observed in injected femurs relative to distal femurs. Similar patterns favoring engraft-
ment in the injected femur have been previously reported8,12,17,21. Based on this observation, it has been proposed 
that the high local engraftment efficiency makes IF transplantation an excellent tool for studying the engraftment 
of rare cell populations8,12. The greater number of primitive donor cells in femurs following IF transplantation 
has been interpreted as more efficient retention of primitive cells within the injected femur, coupled with a locally 
increased rate of self-renewal17. However, this interpretation ignores another possible hypothesis: the transient 
retention of donor cells in one bone marrow delivery site compromises their engraftment in distal marrow and 
other hematopoietic organs.
In most animal transplantation studies, animals are conditioned via irradiation. Irradiation liberates niche 
sites or “makes space” for donor HSC, and triggers a niche resident-cell signaling cascade that encourages homing 
of the donor cells13,22. The onset of this signaling cascade in murine bone marrow, and it’s tapering, occurs rapidly. 
There is an inflection point and tapering in the signaling that promotes homing as early as three days post irradi-
ation14,23,24. Most laboratories synchronize these processes by conditioning animals and then transplanting donor 
cells 24–48 hours later. This window of opportunity is sufficient if cells are delivered via IV transplantation, as the 
majority of cells that will home to the murine marrow do so within 2–24 hours post infusion13,25.
The hypothesis that retention of donor cells within a single femur, following IF transplantation, will enhance 
transplant outcomes is contingent on the capacity for the locally engrafted population to subsequently dissemi-
nate throughout the recipient. However, the engraftment and dissemination potential of human HSC in a murine 
host will decrease as the host marrow recovers from irradiation. The engraftment capacity of donor hematopoietic 
cells is a function of both the irradiation dose, as well as the species relationship between the donor and host. 
Irradiation is an essential step if NSG mice are to be transplanted with human HSC, as otherwise human HSC are 
unable to compete with murine HSC for limited niche occupancy21. In a recent comparative study, human CD34+ 
cell engraftment potential was evaluated in sublethally irradiated and non-irradiated NSG mice21. At 12 weeks, 
peripheral blood hCD45 engraftment was ~60% and 5% for irradiated and non-irradiated mice, respectively. 
When murine HSC were not ‘displaced’ through irradiation, human HSC engraftment was reduced by approxi-
mately 10-fold. Similarly, as murine BM recovers from irradiation, human HSC engraftment efficiency declines. 
Thus, a risk associated with the retention of donor cells within one BM cavity, is that the distal BM recovers from 
conditioning and becomes less receptive to human donor cell repopulation.
Our data suggest that IF transplantation can saturate the injected femur, and yet may not contribute to high 
levels of systemic engraftment (boxed data in Fig. 4C). This observation highlights the tenuous balance between 
the benefits associated with avoiding donor cell loss to vascular non-hematopoietic organs, and the compromised 
outcomes that may result if the majority of donor cells are immediately retained within a localized BM site. A 
single murine femur represents only ~6% of the total BM volume26. Consequently, in this model, the benefits of 
improved localized engraftment are marginal if these cells cannot subsequently and efficiently repopulate distal 
niches. Previous data8 from John Dick’s laboratory aligns with our hypothesis that transient retention of donor 
cells within the injected femur leads to compromised engraftment at distal sites. In their study, clonal analysis was 
performed for engrafted human cells recovered from bones harvested from different regions in mice following 
direct bone marrow transplantation. Their data indicate that (1) a large number of clones populate the injected 
femurs, suggesting that many cells are retained within the injected femur; (2) many of the clones could also be 
found at distal sites, suggesting that clones could multiply in the injected femurs and then spread to distal sites; (3) 
some clones did not spread to distal sites, suggesting heterogeneity in migration capacity, or as we suggest - there 
is a temporal limitation in distal engraftment processes; and (4) some clones could be found at distal sites, but not 
in the injected site, suggesting that some IF injected cells might have leaked or migrated through the blood vessels 
to populate other sites.
While the previous work described above8 and our own study were performed using a short-term engraftment 
model (< 16 weeks), a study from the laboratory of Connie Eaves, using a long-term engraftment model (27 
weeks), demonstrated that the mobility of human HSC was substantially constrained in the BM of NSG mice27. At 
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27 weeks, the distribution of clones was not uniform between different BM sites of mice, when comparing the left 
hind leg, right hind leg and pelvic bones27. In one mouse, 32% of clones were found only in one of the three BM 
sites assessed, while in a second mouse, 53% of clones were found in only one BM site27. Earlier parabiont studies 
suggested that HSC flux between blood and BM occurred frequently and rapidly under homeostatic conditions, 
with 100–400 long-term engrafting HSC present in the circulation of mice at any given time28. Frequent recir-
culation and homing of human long-term HSC in a xenogeneic transplant model would be expected to produce 
a homogeneous engraftment pattern. However, previously published data suggest that human hematopoietic 
clones are not homogenously distributed throughout mice8,27. Our data suggest that the failure of human HSC to 
redistribute throughout the animal can result in both non-uniform spatial engraftment and compromised total 
cell engraftment. Like murine HSC28,29, it is likely that human HSC cyclically egress from niches and enter the 
circulation in mice; however, it appears that their capacity to re-engraft at distal BM sites is significantly impaired 
in NSG mice. Local BM retention of HSC, or their delayed distribution throughout the mouse following IF trans-
plantation, can result in significantly compromised engraftment at distal sites.
Recent human clinical trials failed to deliver enhanced outcomes when allogeneic CB donor cells were deliv-
ered via direct marrow transplantation11. In these studies, a second CB unit was delivered via IV transplantation. 
It is possible that the greater access to distal niches enabled by IV transplantation provides a relative advantage in 
the allogeneic CB transplant setting. However, the underlying concept of localized retention of donor HSC in the 
BM may have merit in an autologous setting. Autologous HSC transplantation can be an effective treatment for 
non-Hodgkin’s lymphoma and multiple myeloma patients. In ~12% of patients, the number of HSC that can be 
mobilized is so low that this therapy is not viable30–32. A robust localized graft, established from a small number 
of autologous HSC may have significant therapeutic potential in this context. Because the graft is autologous, the 
factors that obstruct the competitive repopulation of human cells in the xenogeneic NSG model may not exist. 
Furthermore, IF transplantation may be ideal where genetic modification and engraftment of only a small popu-
lation of HSC is necessary, for instance, to raise an immunological response to a cancer or virus33,34. In both cases, 
it would be more rational to use an autologous or syngeneic animal model and to ensure that spatial engraftment 
artifacts are considered during experimental design.
A further observation from our study was that co-administration of MSC with CD34+ cells did not appear 
to be improve hematopoietic engraftment. This is in contrast to previous studies, where results indicated that 
co-administration of MSC with CD34+ cells improved engraftment outcomes in NOD/SCID mice when deliv-
ered by IV35,36 and IF37. Our results parallel previous NSG studies, which reported no improvement in human 
CD34+ engraftment in the BM with co-administration of MSC38. We were unable to identify a study that directly 
compared co-administration of MSC in these two different mouse models (NOD/SCID vs NSG). Engraftment 
of human HSC in NOD/SCID mice is compromised by immune barriers such as the presence of murine natu-
ral killer cells39. The evolution of the NSG mouse reflects intensive research efforts to develop an animal model 
more tolerant of human xenografts, and increasingly, xenogeneic transplant studies are performed using the NSG 
mouse over other immunodeficient strains. The additional repression of the immune system in NSG mice results 
in 3.6-fold more sensitivity in detecting SCID repopulating cells than in NOD/SCID mice39. MSC are known to be 
immunomodulatory40, and others have proposed that their immunomodulatory activity might influence engraft-
ment41. Thus the benefit of MSC35–37 may have been amplified in previous studies where the recipient NOD/SCID 
mice had a more active immune system. In our study, the immunomodulatory benefits of MSC did not appear to 
influence human HSC engraftment in the more immune compromised NSG mice.
In summary, we show that IF transplantation of human CD34+ cells enhanced local BM engraftment relative 
to distal hematopoietic sites in NSG mice. Engraftment at distal BM was compromised by the transient retention 
of donor cells within the injected femur, even in conditions that ultimately led to saturation of the local BM 
with human hematopoietic cells. We conclude that in this xenogeneic model, IF transplantation enhances local 
engraftment at the expense of engraftment at distal sites. We suggest that this artifact should be considered when 
utilizing IF transplantation in xenogeneic animal models.
Materials and Methods
Mice. NSG mice were purchased from the Jackson Laboratory42 and bred in the Animal Facility at the 
Translational Research Institute (TRI) in Brisbane. Adult mice (2–4 months) were sublethally irradiated with 
250 cGy using a Gamma Cell 40 Caesium source 24 hours before human cell transplantation. The University of 
Queensland (UQ) and the Queensland University of Technology (QUT) Animal Ethics Committees authorized 
the animal procedures described here. All animal procedures were carried out in accordance with the approved 
guidelines (Ethics number: 1300000644).
CD34+ cell isolation. CB was collected at the Mater Hospital in Brisbane following full-term births with 
the informed written consent from mothers. Ethics approval was granted by the Mater Health Services Human 
Research Ethics Committee and the Queensland University of Technology Human Ethics Committee, with all 
methods carried out in accordance with the approved guidelines (Ethics number: 1100000210). CD34+ cell isola-
tion from CB was performed within 24 hours of collection. CB was diluted with PBS containing 2 mM EDTA and 
mononucleated cells were isolated by Ficoll-Paque (GE Healthcare) density centrifugation. CD34+ progenitor 
cells were purified using the CD34 MicroBead Kit-UltraPure and AutoMACS Pro Seperator (both from Miltenyi) 
as per manufacturer’s instructions. CD34+ cells were cryopreserved in 10% DMSO and 90% FBS, slowly frozen 
to − 80 °C overnight and stored in liquid nitrogen until use. CD34+ cells were pooled from multiple CB donors to 
obtain sufficient cells for experiments. CD34-purity was assessed prior to cell culture by anti-human CD34 anti-
body (Miltenyi) staining and flow cytometry on the LSRII (Becton Dickinson), achieving more than 90% purity.
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MSC isolation and expansion. Human adult BM MSC isolation, culture and characterization were per-
formed as previously described [14]. Ethics approval for aspirate collection was granted by the Mater Health 
Services Human Research Ethics Committee and the Queensland University of Technology Human Ethics 
Committee (Ethics number: 1000000938). Briefly, mononuclear cells were isolated from 20 ml of BM aspirates 
using density gradient centrifugation. MSC were enriched using plastic adherence overnight in a 20% O2 and 5% 
CO2 atmosphere at 37 °C in MSC expansion medium containing: low glucose DMEM (Life Technologies), 10% 
fetal bovine serum (FBS; Life Technologies), 10 ng/mL fibroblast growth factor-1 (FGF-1; Peprotech), and 100 U/
ml penicillin/streptomycin (PenStrep; Life Technologies). After discarding the loose cells and replenishing the 
medium, MSC were further expanded in a 2% O2 and 5% CO2 atmosphere at 37 °C. Cells were passaged at 80% 
confluence using 0.25% trypsin/EDTA (Life Technologies) and new flasks were re-seeded at ~1,500 cells per cm2. 
MSC were used at passage 3. Using flow cytometry, cells were characterized for their expression of CD44, CD90, 
CD73, CD105, CD146, CD45, CD34, HLA-DR, and tri-lineage differentiation capacity, as described previously43.
Cell culture preparation and mouse transplants. The four different experimental groups assessed for 
human hematopoietic cell engraftment in NSG mice are represented schematically in Fig. 1. The four groups 
included: (1) IV delivery of CD34+ by retro-orbital injection; (2) direct marrow delivery of CD34+ by IF injection 
(3) co-delivery of a suspension of CD34+ and MSC by IF; and (4) co-delivery of CD34+ and MSC in 3D spheroids 
by IF. All cell cultures were established 24 hours prior to injecting mice. Cultures were prepared in 6-well plates 
with 5 × 104 CD34+, with or without 5 × 105 MSC, as indicated, in 4 mL of X-Vivo 15 media (Lonza) supplemented 
with 10 ng/ml of SCF (Amgen), TPO peptide (Auspep Pty Ltd.44), Flt-3 ligand (Miltenyi) and FGF-1. For groups 
1, 2 and 3, cultures were initiated in 6-well tissue culture plates. The plates used for group 2 were additionally 
pre-coated with fibronectin (BD Biosciences) to allow for MSC attachment. Group 4 cultures were prepared in 
AggreWell 400Ex 6-well plates (StemCell Technologies) that were rinsed with 5% Pluronic-F127 (Sigma) to prevent 
cell adherence45. Since a single well of the AggreWell plate surface contained ~4,700 microwells, at the above cell 
seeding density used, ~4,700 spheroids were produced per well, consisting of ~110 MSC and ~10 CD34+ cells each.
Prior to cell injection in NSG mice, culture wells for each experimental group were pooled and concentrated. 
Group 2, which contained CD34+ cells and MSC adhered to the culture plate well, were first trypsinized to liberate 
the cells from the culture surface. NSG mice from each group were injected such that, each mouse received the 
equivalent of cells from a single well of the original 6-well plate, or 5 × 104 CD34+ with or without 5 × 105 MSC, as 
indicated. Cells were delivered in 100 μl of fresh X-Vivo 15 media for IV injections and in 10 μl for IF injections. For 
IV injections, mice were anaesthetized by isofluorane inhalation and cells injected in the retro-orbital sinus. For IF 
injections, mice were anaesthetized with 10 mg/ml ketamine/xylazine. A pilot hole was drilled through the joint into 
the right femur with a 26-guage needle, and the cells were injected with a 27-guage microsyringe needle (Hamilton).
Flow cytometry quantification of human cell engraftment. Transplanted NSG mice were 
assessed after eight weeks for human hematopoietic cell engraftment. Mice were euthanized by CO2 asphyx-
iation and peripheral blood, femurs and spleen were harvested. PB was collected via cardiac puncture into 
heparin-containing tubes and lysed of red blood cells using lysis buffer (eBioscience) as per manufacturer’s 
instructions. Spleens were disrupted by grinding between two frosted glass cover slips. Left and right femurs from 
each mouse were crushed separately using a mortar and pestle. All tissue cell preparations were resuspended 
in cold 2% FBS/PBS and passed through a 40 μm cell strainer (Falcon). Approximately 106 cells were used for 
antibody staining and flow cytometry analysis. Prior to antibody staining, cells were resuspended in blocking 
solution: mouse-Fc block (1 μg per sample) (BD Biosciences), 10% normal mouse serum (Life Technologies), 
and 1 mg/ml human IgG (Sigma) for 20 minutes at 4 °C. Fluorescence-conjugated antibodies were used to asses 
the level of human hematopoietic cell engraftment and lineage. Antibodies included human (h)CD45-VioBright 
FITC, hCD34-APC (both from Miltenyi), hCD3-APC_Cy7, hCD15-PE, hCD19-PE_Cy7, hCD33-BV421 (all 
from Biolegend), and mouse (m)CD45-APC (BD Biosciences). Cells were stained with the appropriate antibod-
ies as recommended in the manufacturers’ instructions for 30 minutes at 4 °C. Dead cell exclusion was performed 
with the addition of 7-aminoactinomycin D (7-AAD; Life Technologies). Unstained cells, isotype controls and 
single colour controls were also prepared to facilitate gating and adjust for spectral overlap. Flow cytometry was 
performed on a LSRII (BD Biosciences). 50,000 to 100,000 total events were recorded. Data was analysed using 
FlowJo software (Tree Star). Percentage human engraftment was calculated as: % hCD45+ engraftment = hCD45+ 
cells/(hCD45+ cells + mCD45+ cells) × 100. Positive human engraftment was defined as more than 1% hCD45+ 
in one of the mouse tissues analysed. Non-engrafted mice were excluded from the analysis.
Labeling of CD34+ cells and MSC for fluorescence imaging. CD34+ cells were stained using the 
CellTrace CFSE Cell Proliferation Kit (Life Technologies) and MSC were labelled with CellTracker Red CMTPX 
Dye as per manufacturer’s instructions, using a 5 μM working concentration of dye reagent in each case. 
CFSE-labelled CD34+ cells and CMTPX-labelled MSC were found to be 100% fluorescently labelled with the 
respective dye by flow cytometry. Cell cultures were prepared as described above. Monocultures and co-cultures 
were allowed to establish for 24 hours, at which point loose cells were gently washed away with 5× washes of 
1 ml PBS. For 3D spheroid co-cultures, the cell aggregates were depleted of loose cells by washing them over 
a 35 μm cell strainer (Falcon). Cells were fixed with 4% paraformaldehyde (Sigma), stained with DAPI (Life 
Technologies). Confocal images of spheroids were captured with an Olympus FV1200 confocal microscope.
Statistical Analysis. Statistical analysis was performed using Prism Version 5.0 (GraphPad). Differences 
between transplant groups were tested using the nonparametric Mann-Whitney test and differences between 
engraftment locations were tested using the Wilcoxon rank-sum test. Differences were considered to be signifi-
cant for values of P < 0.05.
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